Clinical trial
Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)
NCT00280631 · Telik, Industry · Completed
Key facts
| NCT number | NCT00280631 |
|---|---|
| Title | Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) |
| Official title | Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Telik, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome (MDS) |
| Intervention type | Drug |
| Interventions | Ezatiostat Hydrochlorine |
| Enrollment | 49 |
| Start date | Feb 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jan 23, 2006 |
| Last update posted | May 31, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: